What are P2Y12 inhibitor drugs?

P2Y12 inhibitor drugs are pharmacologic agents that share a common mechanism (typically targeting P2Y12 receptor). 2 are currently marketed, with 2 more in clinical development.

What are the marketed P2Y12 inhibitor drugs?

Marketed P2Y12 inhibitor drugs include Group P+T, Group P+P.

P2Y12 inhibitor

2 marketed 2 in Phase 3

This page covers all P2Y12 inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting P2Y12 receptor.

Targets

P2Y12 receptor

Marketed (2)

Group P+T · Huazhong University of Science and Technology · Cardiovascular
This drug works by inhibiting the P2Y12 receptor, preventing platelet activation and aggregation.
Group P+P · Huazhong University of Science and Technology · Cardiovascular
This drug works by inhibiting the P2Y12 receptor, preventing platelet activation and aggregation.

Phase 3 pipeline (2)

Standard dose PTCY · Shanghai Jiao Tong University School of Medicine · Cardiovascular
PTCY is a small molecule that targets the P2Y12 receptor.
P2Y12 inhibitor de-escalation · Azienda Ospedaliera Universitaria Policlinico "G. Martino" · Cardiovascular
P2Y12 inhibitors block the action of ADP on the P2Y12 receptor, preventing platelet activation and aggregation.